AstraZeneca caps monthly cost for asthma-COPD drugs at $35 a month under its assistance programs

Pascal Soriot, CEO of AstraZeneca.

AstraZeneca will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine under its programs.

Expanding the savings programs will help make its inhalers more affordable to patients with asthma and chronic obstructive pulmonary disease (COPD), including uninsured and underinsured.

Pascal Soriot, CEO of AstraZeneca, said: “AstraZeneca’s expanded savings programs build on our longstanding commitment to addressing barriers to access and affordability for patients living with respiratory diseases to ultimately help patients lead healthier lives. We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone. It is critical that Congress bring together key stakeholders to help reform the healthcare system so patients can afford the medicines they need, not just today, but for the future.”

AstraZeneca has been battling with federal regulators over negotiating drug prices for Medicare patients. AstraZeneca employs about 1,500 people in Delaware.

Starting on June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines, including:

  • AIRSUPRA  (albuterol and budesonide)
  • BEVESPI AEROSPHERE  (glycopyrrolate and formoterol fumarate) Inhalation Aerosol
  • BREZTRI AEROSPHERE  (budesonide, glycopyrrolate, and formoterol fumarate) Inhalation Aerosol
  • SYMBICORT  (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol

In addition, AstraZeneca reduced the list price of SYMBICORT on Jan. 1 The company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.

For more than 50 years, AstraZeneca has served respiratory patients by investing in the research and development of new drug-device combinations, as well as next-generation biologics and novel mechanisms to address the vast unmet needs of these chronic, often debilitating diseases. AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.